Arca
Skip to content
Tools
Tools

ALK, EML4: EML4-ALK

Chimeric protein in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 4
  • In phases 1 to 3: 1
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on ALK, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Other 1

Approved4

  • Alectinib
  • Lorlatinib
  • Crizotinib
  • Ceritinib

Phase 30

    Phase 20

      Phase 11

      • PLB1003

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Beijing Pearl Biotechnology Limited Liability Company120%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: EML4-ALK inhibitor.
      AlectinibApprovedRocheSmall moleculeInhibitor44
      LorlatinibApprovedPfizerSmall moleculeInhibitor42
      CrizotinibApprovedPfizerSmall moleculeInhibitor39
      CeritinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor11
      PLB1003Phase 1Beijing Pearl Biotechnology Limited Liability CompanyOtherInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 29 in all, from ClinicalTrials.gov.
      Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCLorlatinibPhase 1Not yet recruitingDana-Farber Cancer InstituteNov 16, 2026
      Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaAlectinibPhase 2Not yet recruitingSt. Jude Children's Research HospitalNov 4, 2026
      Ceritinib Treatment for Recurrent MeningiomasCeritinibPhase 2Not yet recruitingKevin PetreccaOct 23, 2026
      Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsCrizotinibNot applicableActive, not recruitingNational Cancer Center, KoreaOct 23, 2026
      Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsAlectinibPhase 2Not yet recruitingShanghai Zhongshan HospitalSep 21, 2026
      TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-SamplingAlectinib, LorlatinibNot applicableNot yet recruitingKarolinska InstitutetSep 16, 2026
      A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerCrizotinibPhase 3Not yet recruitingGuangzhou JOYO Pharma Co., LtdSep 11, 2026
      Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaCrizotinibPhase 3RecruitingIDEAYA BiosciencesSep 4, 2026
      Molecularly Tailored Therapy in Advanced Pancreatic CancerCrizotinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
      Study of NXP900 With Lorlatinib in ALK+ Lung CancerLorlatinibPhase 1RecruitingNuvectis Pharma, Inc.Aug 25, 2026
      Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibLorlatinibPhase 1RecruitingUniversity of ChicagoAug 24, 2026
      A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung CancerAlectinibPhase 2Not yet recruitingFirst Affiliated Hospital of Fujian Medical UniversityAug 18, 2026
      Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCLorlatinibPhase 2Not yet recruitingGuangdong Association of Clinical TrialsAug 6, 2026
      Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedLorlatinibPhase 4Not yet recruitingHunan Cancer HospitalJun 29, 2026
      Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCLorlatinib—Not yet recruitingSun Yat-sen UniversityJun 29, 2026
      Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLCLorlatinibPhase 4Not yet recruitingQiming WangJun 26, 2026
      OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyAlectinibPhase 1RecruitingM.D. Anderson Cancer CenterJun 18, 2026
      Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyAlectinibPhase 2Not yet recruitingWen-zhao ZHONGMay 7, 2026
      Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Alectinib, CrizotinibPhase 1 / Phase 2Not yet recruitingChina Medical University HospitalMay 1, 2026
      A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionCrizotinibPhase 1Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.Apr 20, 2026
      Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaAlectinib, Crizotinib—RecruitingFirst People's Hospital of HangzhouOct 3, 2025
      Using Tumor Models to Determine TreatmentsCeritinibPhase 2RecruitingUniversity Health Network, TorontoFeb 6, 2025
      Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCCrizotinib—Not yet recruitingNational Cancer Center, ChinaNov 19, 2024
      Antineoplastic Drugs in Elderly PatientsCeritinib—RecruitingShandong UniversityJul 20, 2022
      A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)CeritinibPhase 1 / Phase 2RecruitingNuvalent Inc.May 20, 2022
      Improving Public Cancer Care by Implementing Precision Medicine in NorwayCeritinibPhase 2RecruitingOslo University HospitalMar 26, 2021
      Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationCeritinibPhase 2RecruitingHunan Province Tumor HospitalMar 26, 2020
      Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCCeritinibPhase 1Active, not recruitingH. Lee Moffitt Cancer Center and Research InstituteAug 2, 2018
      Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyCeritinibPhase 4Active, not recruitingNovartis PharmaceuticalsOct 23, 2015

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3883330, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.